A single injection once per 8 weeks vs once per 4 weeks demonstrated similar levles of skin clearance, for AD patients 12 years and older, according to a Fall Clinical announcement.
Lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) demonstrated similar levels of skin clearance in patients with moderate-to-severe atopic dermatitis (AD) when administered once every 8 weeks compared to every 4 weeks, showing the potential for a less frequent maintenance dosing regimen. Details were announced and presented at the 2025 Fall Clinical Dermatology Conference, occurring in Las Vegas, Nevada, from October 23 through 26, 2025.1
According to a press release from Eli Lilly, the long-term data for the single 250 mg injection of the interleukin-13 (IL-13) inhibitor that "selectively blocks IL-13 signaling with high binding affinity," were from the phase 3 ADjoin extension trial (NCT04392154) of lebrikizumab.1,2 According to ClinicalTrials.gov, ADjoin consists of 1153 patients aged 12 years and older.
"For people managing the persistent symptoms of eczema, hesitancy about frequent injections can add to the already heavy toll of this disease," said Peter Lio, MD, author of the ADjoin study and clinical assistant professor of Dermatology and Pediatrics, Northwestern University, in a statement. "With as few as six maintenance doses per year, [lebrikizumab-lbkz] would give patients and providers more flexibility, which may reduce treatment burden for patients with busy lives."
According to Lilly, these data from the ADjoin extension study, among other data, have been submitted to the FDA for a potential label update. Additionally, a study investigating lebrikizumab-lbkz maintenance dosing of 500 mg administered once every 12 weeks is underway.
"Managing moderate-to-severe atopic dermatitis involves ongoing cycles of flare-ups and itching, which can be difficult for people with eczema," said Kristin Belleson, President and CEO of the National Eczema Association. "Treatment options that have the potential to reduce the time people spend managing symptoms could give them more time to focus on what matters most."
In a previous Q&A interview with Contemporary Pediatrics, Lio highlighted data from the ADapt (NCT05369403) study, evaluating lebrikizumab in patients previously treated with dupilumab (Dupixent; Sanofi and Regeneron).2
"The focus was on patient-reported outcomes (itch and sleep improvements) in this refractory patient population, showing levels of improvement similar to what was seen in the pivotal studies," Lio said in the interview. "This is exciting because many clinicians want to know what to expect for patients who have previously been on dupilumab, and this gives us some reassuring evidence in this important population."
In a separate Q&A discussion, Andrew Alexis, MD, MPH, professor of clinical dermatology and vice chair for diversity and inclusion in the Department of Dermatology at Weill Cornell Medicine, dermatologist at New York-Presbyterian/Weill Cornell Medical Center, and lead ADmirable investigator, highlighted lebrikizumab data among individuals with pigmented skin tones.3
"In this analysis presented at RAD, we presented the 24-week efficacy and safety outcomes of lebrikizumab in adult and adolescent patients with moderate to severe AD and skin of color, a historically underrepresented patient population in clinical trials, for which important data gaps and health care disparities exist," said Alexis.
"The study included innovative measures of postinflammatory pigment alteration associated with AD using a novel scale called PDCA. Lebrikizumab improved AD signs and symptoms (including itch) through 24 weeks of treatment across Fitzpatrick skin phototypes, with continued improvement from weeks 16 to 24."
References:
